All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L2 - all population, pembrolizumab (2mg/kg) vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.86 [0.67; 1.10]
0.86 [0.67 ; 1.10 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 359 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.57 [0.45; 0.73]
0.57 [0.45 ; 0.73 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 359 NA not evaluable objective responses (ORR)detailed results KEYNOTE-002 (2 mg/kg), 2015 6.11 [2.77; 13.47]
6.11 [2.77 ; 13.47 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 359 NA not evaluable TRAE (any grade)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.56 [0.34; 0.93]
0.56 [0.34 ; 0.93 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.44 [0.25; 0.76]
0.44 [0.25 ; 0.76 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.85 [0.32; 2.25]
0.85 [0.32 ; 2.25 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 1.46 [0.40; 5.25]
1.46 [0.40 ; 5.25 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.10 [0.01; 0.81]
0.10 [0.01 ; 0.81 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
0.96 [0.06 ; 15.48 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
0.96 [0.06 ; 15.48 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.48 [0.02; 14.37]
0.48 [0.02 ; 14.37 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.23 [0.05; 1.11]
0.23 [0.05 ; 1.11 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
1.93 [0.06 ; 57.80 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.07 [0.00; 1.17]
0.07 [0.00 ; 1.17 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
1.93 [0.06 ; 57.80 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.17; 21.50]
1.93 [0.17 ; 21.50 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24]
0.12 [0.01 ; 2.24 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.08 [0.00; 1.40]
0.08 [0.00 ; 1.40 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.01; 5.32]
0.24 [0.01 ; 5.32 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
1.93 [0.06 ; 57.80 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24]
0.12 [0.01 ; 2.24 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.03; 2.13]
0.24 [0.03 ; 2.13 ] KEYNOTE-002 (2 mg/kg), 2015 1 0% 349 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 23:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 69
- treatments: 576